胰腺癌患者血浆中MicroRNA的表达及临床意义  

Expression and clinical significance of Micro RNA in peripheral blood of patients with pancreatic cancer

作　　者：左利平[1] 尚亚飞[1] 韩坤[1] 庄坤[1] 闫媛[1] 张欣[1] 

机构地区：[1]西安市中心医院,陕西西安710003

出　　处：《基层医学论坛》2017年第7期777-779,共3页The Medical Forum

基　　金：陕西省科技厅资助项目肿瘤机理研究(2014K 11-01-01-10)

摘　　要：目的检测胰腺癌患者血浆中mi R-21、mi R-155的表达水平,评价其临床意义。方法分别收集性别、年龄相匹配的32例胰腺癌患者,27例正常对照组的血浆标本和临床资料,采用RT-PCR法检测血浆中mi R-21、mi R-155的相对表达量,采用电化学方法检测同样本中的CA19-9含量,评估其临床诊断价值。结果胰腺癌患者血浆中两种mi RNAs的表达量较正常对照组均明显升高(P<0.05);2个特异性mi RNA联合CA19-9,诊断胰腺癌的敏感性和特异性均显著提高。结论血浆中mi R-21、mi R-155检测可为胰腺癌的早期诊断提供一个新方法。Objective To detect the microRNAs in plasma with patients of pancreatic cancer, and evaluate its diagnostic value. Methods Age-and-gender-matched plasma samples and complete clinical data were collected from 32 pancreatic cancer patients as well as 27 nomal controls, and the quantitive reverse transcription polymerase chain reaction （qRT-PCR） was employed to detect the miR-21 and miR-155 in the plasma,and （ECL） was employed to detect CA19-9 to evaluate the value of clinical diagnosis through the statistical analysis. Results the two miRNAs （miR-21 and miR-155） in patients with pancreatic cancer were increased （P〈0.05） compared to control group.The diagnostic sensitivity and specificity significandy increase after combined the two miRNAs and CA19-9.Conclusion The miR-21 and miR-155 in plasma may provide a new method in the early diagnosis of pancreatic cancer.

关 键 词：胰腺癌 早期诊断 MIR-21 MIR-155 CA19-9 

分 类 号：R735.9[医药卫生—肿瘤]